# Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

> **NCT03278782** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Angioimmunoblastic T-Cell Lymphoma
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Refractory Mycosis Fungoides
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT03278782
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-14
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278782, "Study of Pembrolizumab (MK-3475) in Combination With Romidepsin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03278782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*